Specific adverse events · women with PMS
1 finding from 1 review
Symptoms score: Premenstrual Daily Questionnaire (PDQ) Scale from 0 to 30, with a higher score indicating a worse outcome over 8 months · women with PMS
1 finding from 1 review
Withdrawals due to adverse events · women with PMS
It is very uncertain whether dose comparison: oestrogen 100 µg patch changes adverse events ‐ withdrawal rates over 8 months' compared with 200 µg patch plus progestogen (very low certainty).
1 finding from 1 review
Adverse events ‐ specific side effects attributed to oestrogen over 8 months' · women with PMS
It is very uncertain whether dose comparison: oestrogen 100 µg patch changes adverse events ‐ specific side effects attributed to oestrogen over… compared with 200 µg patch plus progestogen (very low certainty).
1 finding from 1 review
Quality of life: change in symptom severity score · women with uterine fibroids
1 finding from 1 review
Abnormal uterine bleeding: amenorrhoea · uterine fibroids
SPRM showed no clear difference in abnormal uterine bleeding: amenorrhoea compared with leuprolide acetate (moderate certainty).
1 finding from 1 review
Pelvic pain · uterine fibroids
1 finding from 1 review
Adverse effects: SPRM‐associated endometrial changes · uterine fibroids
SPRM probably leads to higher adverse effects: SPRM‐associated endometrial changes compared with leuprolide acetate (moderate certainty).
1 finding from 1 review
Quality of life: change in health‐related quality of life score · women with uterine fibroids
1 finding from 1 review
Abnormal uterine bleeding: change in menstrual blood loss · women with uterine fibroids
1 finding from 1 review
Abnormal uterine bleeding: amenorrhoea · women with uterine fibroids
SPRM probably leads to higher abnormal uterine bleeding: amenorrhoea compared with placebo (moderate certainty).
1 finding from 1 review
Pelvic pain · women with uterine fibroids
1 finding from 1 review
Adverse effects: SPRM‐associated endometrial changes · women with uterine fibroids
SPRM may leads to higher adverse effects: SPRM‐associated endometrial changes compared with placebo (low certainty).
1 finding from 1 review
Quality of life: change in symptom severity score · uterine fibroids
1 finding from 1 review
Quality of life: change in health‐related quality of life score · uterine fibroids
1 finding from 1 review
Abnormal uterine bleeding: change in menstrual blood loss · uterine fibroids
1 finding from 1 review
Live birth · women treated by operative hysteroscopy for uterine pathology associated with subfertility or adverse pregnancy outcome
It is very uncertain whether any anti‐adhesion therapy changes live birth a compared with placebo or no treatment following operative hysteroscopy (very low certainty).
1 finding from 1 review
Presence of intrauterine adhesions at second‐look hysteroscopy (6‐12 weeks) · women treated by operative hysteroscopy for uterine pathology associated with subfertility or adverse pregnancy outcome
Any anti‐adhesion therapy may leads to lower presence of intrauterine adhesions at second‐look hysteroscopy… compared with placebo or no treatment following operative hysteroscopy (low certainty).
1 finding from 1 review
Live birth · women treated by operative hysteroscopy for uterine pathology
Any anti‐adhesion therapy A showed no clear difference in live birth a compared with anti‐adhesion therapy B following operative hysteroscopy (low certainty).
1 finding from 1 review
Presence of intrauterine adhesions at second‐look hysteroscopy (6‐12 weeks) · women treated by operative hysteroscopy for uterine pathology
Any anti‐adhesion therapy A may leads to lower presence of intrauterine adhesions at second‐look hysteroscopy (6‐12… compared with anti‐adhesion therapy B following operative hysteroscopy (low certainty).
1 finding from 1 review